Minervax
PrivateLast Round
Series C
Oct 11, 2023
Est. Valuation
$7.91M
Total Funding Raised
$173.64M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Minervax is a biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS) for maternal immunization and older adults.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Minervax Comparables
Compare Minervax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inventprise | 86% | |
| Pfizer | 77% | |
| ReNewVax Ltd. | 70% |
Minervax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 11, 2023 | ||||
| Debt | Dec 15, 2022 | ||||
| Series B | Dec 15, 2020 | ||||
| VC Round | Jan 21, 2019 | ||||
| Series A Extension | Feb 15, 2016 | ||||
Series A | Jan 9, 2014 |
Key People
Founding team and executive leadership
Minervax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heartcore Capital | Seed, Series A Extension |
| EQT Life Sciences | Series C |
| Trill Impact | Series C |
| Lund University Innovation System | Seed |
| LF Investment | Debt, Series C, Series A, Series B, Series A Extension |
| Trill Impact Ventures | Series C, Debt |
| Lauritzen Fonden | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 118% MoM.
- Jun 18, 2026
Monthly visitors grew 38% MoM.
Minervax Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Minervax's valuation, stock price, and market status.
Is Minervax a public or private company?
Minervax is a private company.
What is the current stock price of Minervax?
Minervax is a private company, so its shares have no public market price. Caplight tracks Minervax's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Minervax worth (valuation)?
Minervax's valuation is estimated at $7.9M based on funding round data.
Can I buy Minervax stock?
Minervax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Minervax's last funding round?
Minervax's most recent funding round was Series C on October 11, 2023.
Who are the main investors in Minervax?
Key investors in Minervax include EQT Life Sciences, Trill Impact Ventures, OrbiMed, Novo Holdings, Pureos Bioventures.
Will Minervax IPO soon?
No public IPO plans have been announced for Minervax.
How can I track Minervax secondary market activity?
Caplight tracks bids, offers, and trades in Minervax's shares on secondary markets.